Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluticasone furoate
Drug ID BADD_D00946
Description Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Indications and Usage Fluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label][F4364]. The fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitis[FDA Label][A177130].
Marketing Status approved
ATC Code R01AD12; R03BA09
DrugBank ID DB08906
KEGG ID D06315
MeSH ID C523187
PubChem ID 9854489
TTD Drug ID D0Y7JU
NDC Product Code 47848-057; 64918-1915; 0135-0615; 64918-1910; 64918-1916; 22552-0042; 63379-083; 55018-302; 58175-0553; 0135-0616; 63592-3370; 0173-0874; 0173-0888; 50090-5967; 49076-6452; 59057-010; 0173-0876; 50090-6075; 15308-2021; 52482-008; 63379-084; 49076-6451; 59057-009; 64918-1117
UNII JS86977WNV
Synonyms fluticasone furoate
Chemical Information
Molecular Formula C27H29F3O6S
CAS Registry Number 397864-44-7
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemoptysis02.11.04.009; 24.07.01.006; 22.02.03.004--Not Available
Headache17.14.01.001--
Herpes simplex11.05.02.001; 23.11.05.004--Not Available
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.001345%
Hypertensive crisis24.08.01.0010.000611%Not Available
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.001--Not Available
Infection11.01.08.002--Not Available
Intestinal perforation07.04.06.002--Not Available
Intracranial aneurysm24.02.04.001; 17.08.06.001--Not Available
Intraocular pressure increased13.07.04.002--Not Available
Lacrimation increased06.08.02.004--
Laryngeal pain22.12.03.010--
Loss of consciousness17.02.04.0040.000611%Not Available
Lung disorder22.02.07.001--Not Available
Macular degeneration06.09.03.001--Not Available
Middle insomnia19.02.01.003; 17.15.03.003--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Myalgia15.05.02.0010.001345%
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.001--
Nasal dryness22.04.03.002--Not Available
Nasal polyps22.04.03.010; 16.38.01.001--Not Available
Nasal septum deviation22.04.03.019--Not Available
Nasal septum perforation22.04.03.003--Not Available
Nasal septum ulceration22.04.03.016--Not Available
Nasopharyngitis11.01.13.002; 22.07.03.002--Not Available
Nausea07.01.07.0010.001222%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages